Galectin-3 as a potential target to prevent cancer metastasis

Clinical Medicine Insights: Oncology

Volumn 9, Issue , 2015, Pages 113-121

  Ahmed, Hafiz ^a   Alsadek, Dina M M ^b  

^a GlycoMantra   (United States)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Angiogenesis; Apoptosis; Galectin 3; TF disaccharide; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CD7 ANTIGEN; CD98 ANTIGEN; COMPLEMENTARY DNA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEXAMETHASONE; DOXORUBICIN; FAS ANTIGEN; GALECTIN 3; GAMMA INTERFERON; GCS 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MELPHALAN; PROTEIN MCL 1; PROTEIN NOXA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL INTERACTION; CELLULAR DISTRIBUTION; EXTRACELLULAR MATRIX; HUMAN; IMMUNITY; LIGAND BINDING; METASTASIS POTENTIAL; NONHUMAN; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; TISSUE GROWTH; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84948989451     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S29462     Document Type: Article

References (143)

1. Ahmed H, Du SJ, O'Leary N, Vasta GR. Biochemical and molecular characterization of galectins from zebrafish (Danio rerio): notochord-specific expression of a prototype galectin during early embryogenesis. Glycobiology. 2004;14:219-32.
2. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev. 2007;26:605-10.
3. Rabinovich GA, Liu FT, Hirashima M, Anderson A. An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol. 2007;66:143-58.
4. Nakahara S, Raz A. Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem. 2008;8:22-36.
5. Vasta GR. Roles of galectins in infection. Nat Rev Microbiol. 2009;7:424-38.
6. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis. 2005;10:267-75.
7. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616-35.
8. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160-71.
9. Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev. 2009;230:114-27.
10. Vladoiu MC, Labrie M, St-Pierre Y. Intracellular galectins in cancer cells: potential new targets for therapy. Int J Oncol. 2014;44:1001-14.
11. 2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 1999;59:6239-45.
12. Massa SM, Cooper DN, Leffler H, Barondes SH. L-29, an endogenous lectin, binds to glycoconjugate ligands with positive cooperativity. Biochemistry. 1993;32:260-7.
13. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2002;277:6852-7.
14. Ochieng J, Green B, Evans S, James O, Warfield P. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta. 1998;1379:97-106.
15. Hsu DK, Zuberi RI, Liu FT. Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem. 1992;267:14167-74.
16. Ochieng J, Platt D, Tait L. Structure-function relationship of a recombinant human galactoside-binding protein. Biochemistry. 1993;32:4455-60.
17. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996;93:6737-42.
18. Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry. 1998;37:4086-92.
19. Raimond J, Zimonjic DB, Mignon C, et al. Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome. 1997;8:706-7.
20. Kadrofske MM, Openo KP, Wang JL. The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys. 1998;349:7-20.
21. Raimond J, Rouleux F, Monsigny M, Legrand A. The second intron of the human galectin-3 gene has a strong promoter activity down-regulated by p53. FEBS Lett. 1995;363:165-9.
22. Guittaut M, Charpentier S, Normand T, Dubois M, Raimond J, Legrand A. Identification of an internal gene to the human Galectin-3 gene with two different overlapping reading frames that do not encode Galectin-3. J Biol Chem. 2001;276:2652-7.
23. Duneau M, Boyer-Guittaut M, Gonzalez P, et al. A novel cell death gene that encodes a mitochondrial protein promoting cytochrome c release. Exp Cell Res. 2005;302:194-205.
24. Seetharaman J, Kanigsberg A, Slaaby R, Leffler H, Barondes SH, Rini JM. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem. 1998;273:13047-52.
25. Collins PM, Hidari KIPJ, Blanchard H. Slow diffusion of lactose out of galectin-3 crystals monitored by X-ray crystallography: possible implications for ligand-exchange protocols. Acta Crystallogr D Biol Crystallogr. 2007;63:415-9.
26. Bian CF, Zhang Y, Sun H, Li DF, Wang DC. Structural basis for distinct binding properties of the human galectins to Thomsen-Friedenreich antigen. PLoS One. 2011;6:e25007.
27. Guha P, Kaptan E, Bandyopadhyaya G, et al. Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci U S A. 2013;110:5052-7.
28. Ahmed H, Allen HJ, Sharma A, Matta KL. Human splenic galaptin: carbohydrate-binding specificity and characterization of the combining site. Biochemistry. 1990;29:5315-9.
29. Ahmed H, Vasta GR. Galectins: conservation of functionally and structurally relevant amino acid residues defines two types of carbohydrate recognition domains. Glycobiology. 1994;4:545-8.
30. Ahmed H, Pohl J, Fink NE, Strobel F, Vasta GR. The primary structure and carbohydrate specificity of a ß-galactosyl-binding lectin from toad (Bufo arenarum Hensel) ovary reveal closer similarities to the mammalian galectin-1 than to the galectin from the clawed frog Xenopus laevis. J Biol Chem. 1996;271:33083-94.
31. Ahmed H, Fink NE, Pohl J, Vasta GR. Galectin-1 from bovine spleen: biochemical characterization, carbohydrate specificity and tissue-specific isoform profiles. J Biochem. 1996;120:1007-19.
32. Liao DI, Kapadia G, Ahmed H, Vasta GR, Herzberg O. Structure of S-lectin, a developmentally regulated vertebrate beta-galactoside binding protein. Proc Natl Acad Sci U S A. 1994;91:1428-32.
33. Bianchet MA, Ahmed H, Vasta GR, Amzel LM. A soluble ß-galactosyl-binding lectin (galectin) from toad (Bufo arenarum Hensel) ovary: crystallographic studies of two protein-sugar complexes. Proteins. 2000;40:378-88.
34. Hirabayashi J, Kasai K. The family of metazoan metal-independent b-galactoside-binding lectins:structure, function and molecular evolution. Glycobiology. 1993;3:297-304.
35. Cooper DNW, Barondes SH. Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism. J Cell Biol. 1990;110:1681-91.
36. Cho M, Cummings RD. Galectin-1, a ß-galactoside-binding lectin in Chinese hamster ovary cells, II. Localization and biosynthesis. J Biol Chem. 1995;270:5207-12.
37. Barboni EA, Bawumia S, Hughes RC. Kinetic measurements of binding of galectin 3 to a laminin substratum. Glycoconj J. 1999;16:365-73.
38. Kariya Y, Kawamura C, Tabei T, Gu J. Bisecting GlcNAc residues on laminin-332 down-regulate galectin-3-dependent keratinocyte motility. J Biol Chem. 2010;285:3330-40.
39. Ochieng J, Leite-Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun. 1998;246:788-91.
40. Fukumori T, Takenaka Y, Yoshii T, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 2003;63:8302-11.
41. Feuk-Lagerstedt E, Jordan ET, Leffler H, Dahlgren C, Karlsson A. Identification of CD66a and CD66b as the major galectin-3 receptor candidates in human neutrophils. J Immunol. 1999;163:5592-8.
42. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem. 1991;266:18731-6.
43. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res. 2001;29:3595-602.
44. Liu L, Sakai T, Sano N, Fukui K. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signaling. Biochem J. 2004;380:31-41.
45. Yu F, Finley RL Jr, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 2002;277:15819-27.
46. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A. Galectin-3, a novel binding partner of beta-catenin. Cancer Res. 2004;64:6363-7.
47. Song S, Mazurek N, Liu C, et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009;69:1343-9.
48. Abedin MJ, Kashio Y, Seki M, Nakamura K, Hirashima M. Potential roles of galectins in myeloid differentiation into three different lineages. J Leukoc Biol. 2003;73:650-6.
49. Elliott MJ, Strasser A, Metcalf D. Selective up-regulation of macrophage function in granulocyte-macrophage colony-stimulating factor transgenic mice. J Immunol. 1991;147:2957-63.
50. Reichert F, Rotshenker S. Galectin-3/MAC-2 in experimental allergic encephalomyelitis. Exp Neurol. 1999;160:508-14.
51. Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WR Jr. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol. 1995;147:1016-28.
52. Dabelic S, Flogel M, Dumic J. Effects of aspirin and indomethacin on galectin-3. Croat Chem Acta. 2005;178:433-40.
53. Dabelic S, Flogel M, Dumic J. Corticosteroids affect galectin-3 expression. Period Biol. 2005;107:175-81.
54. Liu FT, Albrandt K, Mendel E, Kulczycki A Jr, Orida NK. Identification of an IgE-binding protein by molecular cloning. Proc Natl Acad Sci U S A. 1985;82:4100-4.
55. Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von Bernstorff W, Eberlein TJ. Expression and function of galectin-3, a beta- galactoside-binding protein in activated T lymphocytes. J Leukoc Biol. 2001;69:555-64.
56. Hebert E, Monsigny M. Galectin-3 mRNA level depends on transformation phenotype in ras-transformed NIH 3T3 cells. Biol Cell. 1994;81:73-6.
57. Fogel S, Guittaut M, Legrand A, Monsigny M, Hébert E. The tat protein of HIV-1 induces galectin-3 expression. Glycobiology. 1999;9:383-7.
58. Hsu DK, Hammes SR, Kuwabara I, Greene WC, Liu FT. Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. Am J Pathol. 1996;148:1661-70.
59. Dumic J, Lauc G, Flogel M. Expression of galectin-3 in cells exposed to stress-Roles of jun and NF-kappaB. Cell Physiol Biochem. 2000;10:149-58.
60. Stock M, Schäfer H, Stricker S, Gross G, Mundlos S, Otto F. Expression of galectin-3 in skeletal tissues is controlled by Runx2. J Biol Chem. 2003;278:17360-7.
61. Costessi A, Pines A, D'Andrea P, et al. Extracellular nucleotides activate Runx2 in the osteoblast-like HOBIT cell line: a possible molecular link between mechanical stress and osteoblasts' response. Bone. 2005;36:418-32.
62. Ahmed H, Banerjee PB, Vasta GR. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun. 2007;358:241-6.
63. Ruebel KH, Jin L, Qian X, et al. Effects of DNA methylation on galectin-3 expression in pituitary tumors. Cancer Res. 2005;65:1136-40.
64. Ahmed H, Cappello F, Rodolico V, Vasta GR. Evidence of heavy methylation in the galectin-3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol. 2009;2:146-56.
65. Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer. 2010;2:17-33.
66. Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 2007;64:1679-700.
67. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272-6.
68. Fukumori T, Takenaka Y, Oka N, et al. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res. 2004;64:3376-9.
69. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem. 2004;279:34922-30.
70. Colnot C, Ripoche MA, Scaerou F, Foulis D, Poirier F. Galectins in mouse embryogenesis. Biochem Soc Trans. 1996;24:141-6.
71. Poirier F. Roles of galectins in vivo. Biochem Soc Symp. 2002;69:95-103.
72. Mercer N, Guzman L, Cueto Rua E, et al. Duodenal intraepithelial lymphocytes of children with cow milk allergy preferentially bind the glycan-binding protein galectin-3. Int J Immunopathol Pharmacol. 2009;22:207-17.
73. Dumont P, Berton A, Nagy N, et al. Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest. 2008;88:896-906.
74. Cao Z, Said N, Amin S, et al. Galectins-3 and -7, but not galectin-1, play a role in re-epithelialization of wounds. J Biol Chem. 2002;277:42299-305.
75. Kaji Y, Amano S, Usui T, et al. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci. 2003;44:521-9.
76. Kang EH, Moon KC, Lee EY, et al. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus. 2009;18:22-8.
77. Won YS, Jeong ES, Park HJ, et al. Upregulation of galectin-3 by Corynebacterium kutscheri infection in the rat lung. Exp Anim. 2007;56:85-91.
78. Silva-Monteiro E, Reis Lorenzato L, Kenji Nihei O, et al. Altered expression of galectin-3 induces cortical thymocyte depletion and premature exit of immature thymocytes during Trypanosoma cruzi infection. Am J Pathol. 2007;170:546-56.
79. Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol. 2004;165:1931-41.
80. Pacis RA, Pilat MJ, Pienta KJ, et al. Decreased galectin-3 expression in prostate cancer. Prostate. 2000;44:118-23.
81. Xu XC, Sola Gallego JJ, Lotan R, El-Naggar AK. Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms. Int J Oncol. 2000;17:271-6.
82. Wang L, Friess H, Zhu Z, et al. Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest. 2000;80:1233-41.
83. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol. 1999;187:481-9.
84. Fautsch MP, Silva AO, Johnson DH. Carbohydrate binding proteins galectin-1 and galectin-3 in human trabecular meshwork. Exp Eye Res. 2003;77:11-6.
85. Shimonishi T, Miyazaki K, Kono N, et al. Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol. 2001;32:302-10.
86. Moutsatsos IK, Wade M, Schindler M, Wang JL. Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci U S A. 1987;84:6452-6.
87. Niida S, Amizuka N, Hara F, Ozawa H, Kodama H. Expression of Mac-2 antigen in the preosteoclast and osteoclast identified in the op/op mouse injected with macrophage colony-stimulating factor. J Bone Miner Res. 1994;9:873-81.
88. Wollenberg A, de la Salle H, Hanau D, Liu FT, Bieber T. Human keratinocytes release the endogenous beta-galactoside-binding soluble lectin immunoglobulin E (IgE-binding protein) which binds to Langerhans cells where it modulates their binding capacity for IgE glycoforms. J Exp Med. 1993;178:777-85.
89. Reichert F, Saada A, Rotshenker S. Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: phagocytosis and the galactose-specific lectin MAC-2. J Neurosci. 1994;14:3231-45.
90. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E. Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer. 1994;56:474-80.
91. Lotan R, Belloni PN, Tressler RJ, Lotan D, Xu XC, Nicolson GL. Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. Glycoconj J. 1994;11:462-8.
92. Truong MJ, Gruart V, Kusnierz JP, et al. Human neutrophils express immunoglobulin E (IgE)-binding proteins (Mac-2/epsilon BP) of the S-type lectin family: role in IgE dependent activation. J Exp Med. 1993;177:243-8.
93. Truong MJ, Gruart V, Liu FT, Prin L, Capron A, Capron M. IgE binding molecules (Mac-2/epsilon BP) expressed by human eosinophils. Implication in IgE-dependent eosinophil cytotoxicity. Eur J Immunol. 1993;23:3230-5.
94. Craig SS, Krishnaswamy P, Irani AM, Kepley CL, Liu FT, Schwartz LB. Immunoelectron microscopic localization of galectin-3, an IgE binding protein, in human mast cells and basophils. Anat Rec. 1995;242:211-9.
95. Smetana K, Holíková Z, Klubal R, et al. Coexpression of binding sites for A (B) histo-blood group trisaccharides with galectin-3 and Lag antigen in human Langerhans cells. J Leukoc Biol. 1999;66:644-9.
96. Dietz AB, Bulur PA, Knutson GJ, Matasić R, Vuk-Pavlović S. Maturation of human monocyte-derived dendritic cells studied by microarray hybridization. Biochem Biophys Res Commun. 2000;275:731-8.
97. Saada A, Reichert F, Rotshenker S. Granulocyte macrophage colony stimulating factor produced in lesioned peripheral nerves induces the upregulation of cell surface expression of MAC-2 by macrophages and Schwann cells. J Cell Biol. 1996;133:159-67.
98. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29-41.
99. Guha P, Bandyopadhyaya G, Polumuri SK, et al. Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3. Breast Cancer Res Treat. 2014;145:5-22.
100. Bresalier RS, Yan PS, Byrd JC, Lotan R, Raz A. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer. 1997;80:776-87.
101. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 1999;81:519-26.
102. Miyazaki J, Hokari R, Kato S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep. 2002;9:1307-12.
103. Yoshimura A, Gemma A, Hosoya Y, et al. Increased expression of the LGALS3 (galectin 3) gene in human non-small-cell lung cancer. Genes Chromosomes Cancer. 2003;37:59-64.
104. Merseburger AS, Kramer MW, Hennenlotter J, et al. Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate. 2008;68:72-7.
105. Merseburger AS, Kramer MW, Hennenlotter J, et al. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol. 2008;26:637-42.
106. van den Brûle FA, Waltregny D, Liu FT, Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer. 2000;89:361-7.
107. Takenaka Y, Fukumori T, Yoshii T, et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol. 2004;24:4395-406.
108. Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9(2):305-28.
109. Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473-510.
110. Wang Y, Balan V, Gao X, et al. The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis. 2013;4:e753.
111. Cheng D, Liang B, Li Y. Serum galectin-3 as a potential marker for gastric cancer. Med Sci Monit. 2015;21:755-60.
112. Califice S, Castronovo V, Bracke M, van den Brûle F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene. 2004;23:7527-36.
113. Mazurek N, Byrd JC, Sun Y, et al. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. 2012;19:523-33.
114. Kobayashi T, Shimura T, Yajima T, et al. Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug induced apoptosis of human pancreatic carcinoma cells. Clin Exp Metastasis. 2011;28:367-76.
115. Suzuki O, Abe M. Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma. Oncol Rep. 2008;19:743-8.
116. Vaillant F, Merino D, Lee L, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24:120-9.
117. Xin M, Li R, Xie M, et al. Small-molecule Bax agonists for cancer therapy. Nat Commun. 2014;5:4935.
118. Han B, Park D, Li R, et al. Small-molecule Bcl2 BH4 antagonist for lung cancer therapy. Cancer Cell. 2015;27:852-63.
119. Li W, Jian-jun W, Xue-Feng Z, Feng Z. CD133(+) human pulmonary adenocarcinoma cells induce apoptosis of CD8(+) T cells by highly expressed galectin-3. Clin Invest Med. 2010;33:E44-53.
120. Nangia-Makker P, Balan V, Raz A. Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron. 2008;1:43-51.
121. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-8.
122. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem. 1998;254:439-59.
123. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675-87.
124. Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. Glycobiology. 2014;24:886-91.
125. Machado CM, Andrade LN, Teixeira VR, et al. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFβ1-induced macrophages. Cancer Med. 2014;3:201-14.
126. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 1996;56:4530-4.
127. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 2000;6:100-2.
128. Yu LG. The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J. 2007;24:411-20.
129. Yu LG, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007;282:773-81.
130. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 2001;61:4851-7.
131. Zhao Q, Barclay M, Hilkens J, et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer. 2010;9:154.
132. Yu LG. Circulating galectin-3 in the bloodstream: an emerging promoter of cancer metastasis. World J Gastrointest Oncol. 2010;2:177-80.
133. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010;11:1133-46.
134. Idris A, Ghazali NB, Koh D. Interleukin 1β-A potential salivary biomarker for cancer progression? Biomark Cancer. 2015;8(7):25-9.
135. Chen C, Duckworth CA, Zhao Q, Pritchard DM, Rhodes JM, Yu LG. Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res. 2013;19:1693-704.
136. Chen SS, Sun LW, Brickner H, Sun PQ. Downregulating galectin-3 inhibits proinflammatory cytokine production by human monocyte-derived dendritic cells via RNA interference. Cell Immunol. 2015;294:44-53.
137. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344:1788-91.
138. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995;87:348-53.
139. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia. 2005;7:522-7.
140. Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005;65:8350-8.
141. Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010;115:3939-48.
142. Demotte N, Stroobant V, Courtoy PJ, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity. 2008;28:414-24.
143. Demotte N, Bigirimana R, Wieërs G, et al. A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes. Clin Cancer Res. 2014;20:1823-33.